Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common compound help fight COVID-19 and flu? small study explores

NCT ID NCT07254052

Disease control Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study tested whether a sustained-release ammonium chloride formula (with vitamin D) can reduce virus levels in adults with mild or moderate COVID-19 or influenza. 32 participants took either the active formula or a vitamin D-only control twice daily for 10 days. Researchers measured viral load changes and tracked symptoms, hospitalizations, and other outcomes to gather early evidence on this potential add-on treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

32 people

The number who actually took part.

Started

Sep 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years old) with mild or moderate COVID-19 or seasonal influenza infection were recruited at the Outpatients Clinic and the Emergency Department of Sotiria General Hospital for Chest Diseases in Athens, Greece and at "En Ygeia" outpatient clinic. Both inpatients and outpatients were eligible. All participants had a laboratory-confirmed diagnosis by rapid antigen testing and were enrolled within 3-5 days of symptom onset. Patients with severe disease, organ transplantation, pregnancy, or frailty score ≥5 were excluded. A total of 32 participants completed the study procedures.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years. * Positive rapid test for Sars-CoV-2 19 or influenza (performed at the Outpatients Clinic or the Emergency Department). * Informed consent. Exclusion Criteria: * Age \< 18 years. * Pregnancy, and/or lactation. * Denial of Informed Consent. * Known allergy to ammonium chloride or to any of the ACF, or VDF excipients. * Organ transplantation. * Frailty score ≥ 5.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza A and B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 influenza RNA Virus Infections viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza A and B Rna virus infections Viral infection COVID-19

Contacts and locations

Locations

  • En Ygeia Clinic

    Athens, 11524, Greece

  • Sotiria General Hospital

    Athens, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.